Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (split virion, inactivated, high dose)
- Development stage
- Approved
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influenza vaccine (split virion, inactivated, high dose) is an investigational high-dose influenza vaccine developed by Sinovac Biotech. Designed specifically for adults aged 60 years and older, the vaccine contains 60 µg of hemagglutinin (HA) per influenza strain, which is four times the concentration found in standard-dose vaccines (15 µg per strain). This increased antigen content is intended to overcome immunosenescence in the elderly population, eliciting a more robust immune response and higher titers of hemagglutination inhibition (HAI) antibodies. The vaccine is currently being evaluated in Phase I/II clinical trials to assess its safety and immunogenicity compared to standard-dose formulations.
- Other names
- High-dose inactivated split-virion influenza vaccineInfluenza Vaccine (Split Virion), Inactivated (High Dose)
02
Targets
HA (Hemagglutinin)M1 (Influenza virus matrix protein 1)NP (Influenza virus nucleoprotein)Neuraminidase
Beyond the preview
Go deeper on influenza vaccine (split virion, inactivated, high dose).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (split virion, inactivated, high dose).